
Opinion|Videos|November 18, 2024
Exploring Emerging Therapies in Vitiligo
Author(s)Seemal Desai, MD, FAAD
The panelist discusses how emerging targeted therapies like Janus kinase inhibitors and combination treatment approaches are transforming vitiligo management, with treatment selection guided by disease patterns, progression rates and individual patient response, while acknowledging the need for systematic assessment and alternative strategies for treatment-resistant cases.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the most promising new vitiligo treatments?
- How has this knowledge shaped current treatment approaches and new therapies?
- How do vitiligo progression patterns affect treatment decisions and long-term management?
- Describe your process to assess and manage treatment-resistant disease.
- What is the role of newer targeted therapies in such cases?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Myqorzo is now available for rare heart condition at a $108,400 annual price
3
Medicaid tech companies pledge $600 million to help states update systems
4
Why the great pharma-MedTech divide is healthcare’s biggest miss
5





















